Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430

BackgroundCancer and Leukemia Group B trial 9430 was a randomized phase II trial which investigated the safety and activity of four novel doublets in untreated extensive stage small cell lung cancer. The results of the paclitaxel and cisplatin arm have not been reported.Patients and MethodsPatients received paclitaxel 230 mg/m2 followed by cisplatin 75 mg/m2 on day 1 every 21 days. All patients received granulocyte colony stimulating factor 5 μg/kg/d beginning on day 3 of each cycle.ResultsThe patient characteristics of the 34 patients assigned to this treatment arm were: median age 61.5 years (range 41–82), male (76%), performance status 0 (41%), 1 (32%), and 2 (26%). An objective response was observed in 23 patients (68%; 95% confidence interval (CI): 49–83%); 2 complete responses (6%) and 21 partial responses (62%). Median progression-free survival time was 5.6 months (95% CI: 4.8–7.1 month), and median overall survival time was 7.7 months (95% CI: 7.2–12.6 months). The 1-year survival rate observed was 29% (95% CI: 15–45%). Grade 3/4 neutropenia and thrombocytopenia was observed in 5 (15%) and 4 (12%) patients, respectively. Two patients developed febrile neutropenia including one patient who died of neutropenic sepsis. Grade 3/4 nonhematologic observed were: sensory neuropathy in eight patients (24%); and hyperglycemia, malaise and nausea were all observed in four patients (12%).ConclusionsCancer and Leukemia Group B will not pursue further investigation of paclitaxel and cisplatin due to the modest activity and the toxicity observed on this trial.